Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference
VANCOUVER, British Columbia & DALLAS — Alpha Cognition Inc. (Nasdaq: ACOG) ('Alpha Cognition' or the 'Company'), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will share the following poster presentations:
Article content
Bioequivalence of ZUNVEYL
Article content
Article content
, a Galantamine Prodrug to Galantamine Hydrobromide Extended-Release Demonstrated Under
Article content
Steady State
Article content
Conditions (Poster #107147) – July 27
Article content
Bioequivalence of ZUNVEYL
Article content
, a Galantamine Prodrug to Galantamine Hydrobromide Immediate-Release Demonstrated Under
Article content
Fed and Fasting Conditions
Article content
(Poster#107030) – July 28
Article content
, a Galantamine Prodrug, Over a Dosage Range of Five to Fifteen Milligrams Demonstrated Under Fasting Conditions (Poster #107255) -July 30
Article content
'We are excited to present data demonstrating ZUNVEYL's bioequivalence and dose proportionality,' said Dr. Denis Kay, Chief Scientific Officer of Alpha Cognition. 'Given the high unmet need and challenges with current treatments, ZUNVEYL has the potential to offer physicians a well-tolerated therapy with compelling clinical benefits.'
Article content
AAIC is the world's largest forum for dementia research, convening global leaders in basic and clinical science to advance prevention, diagnosis, and treatment of Alzheimer's disease.
Article content
About Alpha Cognition Inc.
Article content
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and cognitive Impairment with mild Traumatic Brain Injury ('mTBI'), for which there are currently no approved treatment options.
Article content
ALPHA-1062 formulated as a delayed release oral tablet (ZUNVEYL), is an FDA approved new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as a sublingual formulation for cognitive Impairment with mTBI.
Article content
ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.
Article content
IMPORTANT SAFETY INFORMATION
Article content
CONTRAINDICATIONS
Article content
ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred.
Article content
WARNINGS AND PRECAUTIONS
Article content
Serious Skin Reactions
Article content
: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered.
Article content
Anesthesia
Article content
Cardiovascular Conditions:
Article content
Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction.
Article content
Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope.
Article content
Gastrointestinal Conditions
Article content
: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.
Article content
Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with ZUNVEYL.
Article content
Genitourinary Conditions:
Article content
Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction.
Article content
Neurological Conditions:
Article content
Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL.
Article content
Pulmonary Conditions:
Article content
Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions.
Article content
ADVERSE REACTIONS
Article content
The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.
Article content
DRUG INTERACTIONS
Article content
Use with Anticholinergics:
Article content
Galantamine has the potential to interfere with the activity of anticholinergic medications.
Article content
Use with Cholinomimetics and Other Cholinesterase Inhibitors:
Article content
A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
Article content
USE IN SPECIFIC POPULATIONS
Article content
Pregnancy:
Article content
Based on animal data may cause fetal harm.
Article content
Hepatic Impairment:
Article content
In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended.
Article content
Renal Impairment:
Article content
In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended.
Article content
These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information.
Article content
Forward-looking Statements
Article content
This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'target,' 'seek,' 'contemplate,' 'continue' and 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the, the long-term benefits of ZUNVEYL, the Company's timing and planned activities and business strategy to launch ZUNVEYL, the potential timing for the availability of ZUNVEYL, the potential future developments of ZUNVEYL, the market size and demand for ZUNVEYL and the Company's potential growth opportunities, capital requirements. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks related to our focus on the long-term care market, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company's filings with the United States Securities and Exchange Commission (the 'SEC'), including those risk factors under the heading 'Risk Factors' in the Company's Form S-1/A registration statement as filed with the SEC on January 10, 2025 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
35 minutes ago
- CTV News
Researchers discover new ancient, armoured fish fossil in Manitoba
A new armoured fish that swam through what is now Manitoba around 390 million years ago has been discovered by researchers at the University of Manitoba. Dr. Melina Jobbins, a postdoctoral fellow at the university, helped lead a team near Lundar, Man., to discover this fish that has been given the name Elmosteus lundarensis. Jobbins said this specific fish is from the mid-Devonian era and prior to this discovery, there isn't much known about fish in Manitoba during this time. 'It's actually great that we can find a bit more and describe this further to show what we have in this province and show people that we have great stuff other than dinosaurs, for example,' said Jobbins. Dr. Melina Jobbins Dr. Melina Jobbins at the dig site in Lundar, Man. Uploaded July 8, 2025. (Dr. Melina Jobbins) Elmosteus lundarensis falls under the placoderm category of fish, which is essentially a fish that had dermal bone around the head area, which acted as armour. Jobbins said this discovery can help us learn even more about the evolution. 'They were also some of the first groups to actually evolve jaws. So they're some of our oldest ancestors. So we get to learn so much about them, about how we got teeth, how we got jaws.' This finding will also help researchers learn what lived in the waters that once covered this province. 'It helps us understand what lived at this time, how much diversity there was. So we can do a lot of ecological analyses.' Dr. Melina Jobbins Dr. Melina Jobbins holds a piece of the new ancient armoured fish fossil found in Manitoba. Uploaded July 8, 2025. (Alex Karpa/CTV News) Manitoba is a fossil hot spot in Canada, the mosasaur being one of the most famous creatures discovered. But this latest discovery helps show there were so many different species that called the province home millions of years ago. 'This group of fish is probably one of the lesser-known groups. So it's really interesting to actually find new fossils and to get to put them on display to show people just how diverse the fossil record of Manitoba actually is,' said Dr. Kirstin Brink, an associate professor of paleontology at the University of Manitoba. As for why Manitoba is so fossil-rich, Brink said Manitoba has the right kind of rock structures to properly preserve fossils. 'A lot of the fossils we find in the province are actually due to mining. So mines that are actually scraping away all the rock to collect it, they'll uncover fossils, kind of by accident. So we can go in there and collect them and preserve them in our museums.' Fish fossil The ancient fish fossil found in Lundar, Man. Uploaded July 8, 2025. (Dr. Melina Jobbins) Jobbins, who said this is a top three discovery for her so far in her career, believes this is just the start of finding more of these kinds of fish in the province. 'I'm sure there'll be more to find as we go there and do fieldwork in the future,' said Jobbins. The Elmosteus lundarensis fossil can be seen on display at the Geological Sciences Museum at the University of Manitoba. - With files from CTV's Alex Karpa
CBC
an hour ago
- CBC
B.C. pet owner warns of blue-green algae dangers following dog's death
"It was kind of like any other day." Kristin Awde's 15-year-old daughter and their young dog were playing in the yard on a sunny June day while Awde cleaned the windows on their summer home at Nicola Lake. Their dog, an English springer spaniel named Romie, wandered down to the lake — not unusual for the pup, who'd been in the lake the day before. But when he emerged, his belly and mouth were covered in green slime. "He looked disoriented and unwell and started vomiting," Awde told CBC's Radio West. She and her daughter tried to clean Romie off, but when he lost consciousness, they got in the car and raced him to the vet for emergency care. Romie died on the veterinarian's examination table, about 45 minutes after he'd entered the water, Awde said. Now, she is warning others of the dangers algae pose for both pets and humans, and is working with her community to ensure there is some sort of oversight of the lake to make sure people know when it's unsafe to swim. B.C. Parks and the Upper Nicola Band have issued warnings about the algae bloom in Nicola Lake, discouraging swimming and drinking lake water. Interior Health Medical Health Officer Dr. Andy Delli Pizzi said in an email to CBC News that a sign is posted at the campgrounds and day use area at Monck Provincial Parks due to the history and risk associated with toxic algae blooms. The Upper Nicola Band said in a July 1 Facebook post it is monitoring the lake. "The water is sick and needs some time to heal," the band said. "Please continue to say prayers for the water as we continue to collect data to narrow in on mitigation measures to help the water." The appearance of blooms of blue-green algae, also known as cyanobacteria, can vary, and in some cases, they aren't even blue-green in colour. Signs of blooms include a musty or earthy odour coming from the water and dead wildlife near the shores. Blue-green algae multiplies quickly in warmer months and produces toxins that are poisonous to people and animals, according to Interior Health. The health authority said boiling water does not remove the toxins, so if you get your water from a source contaminated with blue-green algae, it's best to find an alternate drinking source. Symptoms from blue-green algae include headaches, nausea, fever, sore throat, dizziness, stomach cramping, vomiting, muscle aches, mouth ulcers and rashes. Anyone who becomes unwell after contact with water that may be contaminated with blue-green algae is advised to seek immediate medical or veterinary advice. Accountability Awde said the Nicola Lake community gathered together Monday to discuss the algae bloom and how to prevent further illness and death. She said the hope was that a detection system could be in place, and in the event a toxic bloom was discovered, some sort of mass communication could be shared with the community. "A Facebook post can only go so far," Awde said. She said they'd like to know someone is responsible for preventing and managing algae blooms. "Right now, that seems to be not being managed properly by any government agency," Awde said. "We're at a bit of a loss to try to figure out how we can lobby for something like this to get into place."
CBC
an hour ago
- CBC
Toronto seniors want to bike, study shows, and advocates want the city to help them get riding
Rhoda Potter, a 75-year-old Scarborough resident, says she rides her bike at least once a week. She says the activity is good for health and well-being and that more "older adults" — as she says many people aged 65 and up prefer to be called — would also like to take it up, but safety concerns and a lack of accessible cycling infrastructure are holding them back. Potter was among a group that appealed to the city earlier this week, asking the city to make cycling a key component of Toronto Public Health's strategic plan for 2024 to 2028 — a tenet of which is the creation of age-inclusive communities that work for seniors. "Many times we focus on cycling with the younger groups," Potter told CBC Radio's Metro Morning on Tuesday. "But we see the benefits for the older adults to get out there, get moving. The mobility issues can improve when you're out and about." According to a new report from non-profit Cycle Toronto, only 38 per cent of Torontonians who are 65 and older meet the federally-recommended 150 minutes of weekly physical activity, while 40 per cent of Canadians who are 50-years-old and above are at risk of social isolation. Cycling is part of the solution to both problems, said Alison Stewart, director of advocacy and public policy for Cycle Toronto, at a news conference on Monday where she presented the report. She said active transportation can keep seniors active and outgoing, and age shouldn't stop them. The report noted that 86 per cent of the seniors would like access to learn-to-ride programs, but Stewart said many of the seniors surveyed said that they do not have access to bikes or they don't know how to use Bike Share stations. "Despite the well-documented benefits of biking and walking, seniors are often overlooked in policies and planning that shape the public realm and safety," Stewart said. "If we want to create an equitable, dynamic, vibrant city that's safe and accessible to people of all ages, abilities and incomes, then it really begins by making our streets safer for people walking and biking," she said. The city is committed to long-term improvements to cycling policies, programs and infrastructure, Coun. Chris Moise, chair of the city's board of health, said at Monday's news conference. "We recognize that expanding access to cycling programs and offering a range of e-bikes and adaptive bike styles is crucial to making cycling a viable option for our seniors," he said.
